Soligenix, Inc. (SNGX) stock
SNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.28−0.01 (-2.67%)
Close on Nov 17, 2026Market cap $6.11MP/E –Yield –
Soligenix r&d expenses
Research and development expenses are spending on new products and technology.
Soligenix's R&D Expenses for the twelve months ending Jun 30, 2026 was $6.62M, down 8.6% year over year. For fiscal 2025 it was $7.49M, up 43.3% from the year before. Over ten years it grew 3.3% a year on average. The highest annual figure on record is $9.80M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.49M | +43.3% |
| FY2024 | Dec 31, 2024 | $5.22M | +57.7% |
| FY2023 | Dec 31, 2023 | $3.31M | -58.3% |
| FY2022 | Dec 31, 2022 | $7.94M | -3.0% |
| FY2021 | Dec 31, 2021 | $8.19M | -16.4% |
| FY2020 | Dec 31, 2020 | $9.80M | +20.6% |
| FY2019 | Dec 31, 2019 | $8.12M | +20.3% |
| FY2018 | Dec 31, 2018 | $6.75M | +22.6% |
| FY2017 | Dec 31, 2017 | $5.51M | +28.2% |
| FY2016 | Dec 31, 2016 | $4.30M | -20.4% |
| FY2015 | Dec 31, 2015 | $5.40M | +6.2% |
| FY2014 | Dec 31, 2014 | $5.09M | +0.3% |
| FY2013 | Dec 31, 2013 | $5.07M | +94.4% |
| FY2012 | Dec 31, 2012 | $2.61M | -58.4% |
| FY2011 | Dec 31, 2011 | $6.27M | +4.8% |
| FY2010 | Dec 31, 2010 | $5.99M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $974.09K | -41.9% |
| Q1 FY2026 | Mar 31, 2026 | $1.78M | -8.2% |
| Q4 FY2025 | Dec 31, 2025 | $2.28M | -14.1% |
| Q3 FY2025 | Sep 30, 2025 | $1.58M | +63.5% |
| Q2 FY2025 | Jun 30, 2025 | $1.68M | +234.6% |
| Q1 FY2025 | Mar 31, 2025 | $1.94M | +77.3% |
| Q4 FY2024 | Dec 31, 2024 | $2.66M | +241.9% |
| Q3 FY2024 | Sep 30, 2024 | $968.69K | +17.3% |
| Q2 FY2024 | Jun 30, 2024 | $501.16K | -34.3% |
| Q1 FY2024 | Mar 31, 2024 | $1.10M | +15.7% |
| Q4 FY2023 | Dec 31, 2023 | $777.53K | -67.0% |
| Q3 FY2023 | Sep 30, 2023 | $826.02K | -53.9% |
| Q2 FY2023 | Jun 30, 2023 | $762.70K | -62.8% |
| Q1 FY2023 | Mar 31, 2023 | $946.45K | -45.8% |
| Q4 FY2022 | Dec 31, 2022 | $2.36M | -12.7% |
| Q3 FY2022 | Sep 30, 2022 | $1.79M | -19.9% |
| Q2 FY2022 | Jun 30, 2022 | $2.05M | +5.7% |
| Q1 FY2022 | Mar 31, 2022 | $1.75M | +33.4% |
| Q4 FY2021 | Dec 31, 2021 | $2.70M | -26.2% |
| Q3 FY2021 | Sep 30, 2021 | $2.24M | +76.7% |
| Q2 FY2021 | Jun 30, 2021 | $1.94M | -10.8% |
| Q1 FY2021 | Mar 31, 2021 | $1.31M | -51.5% |
| Q4 FY2020 | Dec 31, 2020 | $3.66M | +122.8% |
| Q3 FY2020 | Sep 30, 2020 | $1.27M | -46.6% |
| Q2 FY2020 | Jun 30, 2020 | $2.17M | +55.6% |
| Q1 FY2020 | Mar 31, 2020 | $2.70M | +130.7% |
| Q1 FY2019 | Mar 31, 2019 | $1.64M | -8.9% |
| Q4 FY2018 | Dec 31, 2018 | $2.37M | +24.9% |
| Q3 FY2018 | Sep 30, 2018 | $1.39M | +130.3% |
| Q2 FY2018 | Jun 30, 2018 | $1.17M | -34.4% |
| Q1 FY2018 | Mar 31, 2018 | $1.80M | +48.1% |
| Q4 FY2017 | Dec 31, 2017 | $1.90M | +120.4% |
| Q3 FY2017 | Sep 30, 2017 | $605.72K | -48.5% |
| Q2 FY2017 | Jun 30, 2017 | $1.78M | +115.5% |
| Q1 FY2017 | Mar 31, 2017 | $1.22M | -14.8% |
| Q4 FY2016 | Dec 31, 2016 | $862.27K | – |
| Q3 FY2016 | Sep 30, 2016 | $1.18M | – |
| Q2 FY2016 | Jun 30, 2016 | $827.83K | – |
| Q1 FY2016 | Mar 31, 2016 | $1.43M | – |
See a number that looks wrong?